MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.720
-0.180
-6.21%
After Hours: 3.050 +0.33 +12.13% 16:08 06/24 EDT
OPEN
2.920
PREV CLOSE
2.900
HIGH
2.950
LOW
2.720
VOLUME
117.70K
TURNOVER
0
52 WEEK HIGH
4.460
52 WEEK LOW
2.650
MARKET CAP
99.24M
P/E (TTM)
-4.2687
1D
5D
1M
3M
1Y
5Y
BrainStorm Announces Presentations at June 2022 Scientific Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at forthcoming ALS and MS scientific conferences in June 2022. Insights into the ALS Phase 3 primary e...
PR Newswire · 05/31 10:00
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 05/25 12:46
BRIEF-Brainstorm Cell Therapeutics Reports Q1 Loss Of 15 Cents Per Share
reuters.com · 05/16 11:49
Recap: Brainstorm Cell Q1 Earnings
  Brainstorm Cell (NASDAQ:BCLI) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 11:32
Brainstorm Cell Q1 EPS $(0.15) Misses $(0.13) Estimate
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 21.05 percent increase over losses of $(0.19) per share from
Benzinga · 05/16 11:16
BrainStorm Cell Therapeutics GAAP EPS of -$0.15 misses by $0.02
BrainStorm Cell Therapeutics press release (NASDAQ:BCLI): Q1 GAAP EPS of -$0.15 misses by $0.02. "We remain firmly committed to addressing the urgent needs of ALS patients by working expeditiously towards
Seekingalpha · 05/16 11:08
Earnings Scheduled For May 16, 2022
  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 05/16 09:18
Brainstorm Cell Earnings Preview
Brainstorm Cell (NASDAQ:BCLI) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Brainstorm Cell will report an earnings per share (EPS) of $-0.13.
Benzinga · 05/13 14:02
More
No Data
Learn about the latest financial forecast of BCLI. Analyze the recent business situations of Brainstorm Cell Therapeutics I through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BCLI stock price target is 11.00 with a high estimate of 14.00 and a low estimate of 8.00.
High14.00
Average11.00
Low8.00
Current 2.720
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 60
Institutional Holdings: 4.27M
% Owned: 11.69%
Shares Outstanding: 36.49M
TypeInstitutionsShares
Increased
10
124.35K
New
3
167.82K
Decreased
9
61.25K
Sold Out
7
533.35K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/Independent Director
Jacob Frenkel
President
Ralph Kern
Chief Executive Officer
Chaim Lebovits
Non-Executive Vice Chairman/Independent Director
Irit Arbel
Chief Financial Officer
Alla Patlis
Chief Operating Officer/Executive Vice President
David Setboun
Executive Vice President/Secretary/Director
Uri Yablonka
Executive Vice President
Stacy Lindborg
Executive Vice President
Anthony Waclawski
Other
Arturo Araya
Director
Menghisteab Bairu
Independent Director
June Almenoff
Independent Director
Anthony Polverino
Independent Director
Malcolm Taub
No Data
No Data
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is focused on development of cellular therapies for the treatment of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD) and other neurodegenerative diseases. The Company offers its services through NurOwn platform. Its BrainStorm Cell Therapeutics Ltd. (Israeli Subsidiary) holds rights to commercialize the technology, NurOwn. Its NurOwn platform leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.